Opsynvi, a fixed-dose combination of macitentan and tadalafil, received FDA approval on February 21, 2024 [1]. This medication is indicated for the treatment of pulmonary arterial hypertension (PAH), WHO group 1, in adults [1].
What is pulmonary arterial hypertension (PAH)?
Pulmonary arterial hypertension is a rare and serious condition characterized by high blood pressure in the arteries of the lungs and the right side of the heart. This elevates the workload on the heart, potentially leading to heart failure [2].
How does Opsynvi work?
Opsynvi combines two different mechanisms to treat PAH. Macitentan is an endothelin receptor antagonist (ERA) that blocks the action of endothelin-1, a substance that constricts blood vessels. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that increases levels of cyclic guanosine monophosphate (cGMP), leading to vasodilation, or the widening of blood vessels [1]. This dual action helps to lower blood pressure in the pulmonary arteries and reduce the strain on the heart [2].
When might patent exclusivity for Opsynvi end?
Information on specific patent expiry dates for Opsynvi is not detailed here, but general timelines for drug patent exclusivity can be influenced by various factors including patent term extensions and any potential legal challenges. DrugPatentWatch.com tracks patent information for pharmaceuticals [3].
What are the risks associated with Opsynvi?
Opsynvi carries several warnings and precautions. These include the risk of fetal toxicity due to the presence of macitentan, as it can cause harm to a fetus. It is contraindicated in pregnancy, and women of childbearing potential must use effective contraception [1]. Other potential risks include hypotension, especially in patients taking other antihypertensive medications or with conditions that predispose them to hypotension. Warnings also exist for patients with hepatic impairment, mild to moderate renal impairment, and those taking strong CYP3A4 inhibitors [1].
How does Opsynvi differ from monotherapies like macitentan or tadalafil alone?
Opsynvi offers a fixed-dose combination, meaning it delivers both macitentan and tadalafil in a single pill. This can simplify treatment regimens for patients compared to taking separate medications for each component, potentially improving adherence. The combination aims to provide a synergistic effect by targeting PAH through two distinct pathways [1].
What clinical data supports the FDA approval of Opsynvi?
The FDA approval was based on studies demonstrating the efficacy and safety of the macitentan and tadalafil combination in treating PAH. These trials evaluated improvements in exercise ability and other relevant clinical endpoints [1].
Who manufactures Opsynvi?
Opsynvi is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
Can patients with PAH take other medications with Opsynvi?
Patients should discuss all medications they are taking with their healthcare provider. Opsynvi may interact with other drugs, particularly strong CYP3A4 inhibitors and inducers, as well as other antihypertensive medications. The drug is also contraindicated in combination with nitrates and strong guanylate cyclase stimulators due to the risk of severe hypotension [1].
---
Sources
1. FDA Approval: Opsynvi (macitentan and tadalafil) tablets https://www.janssen.com/our-products/news/opsynvi-macitentan-and-tadalafil-tablets-fda-approval
2. Pulmonary Arterial Hypertension (PAH) https://www.cdc.gov/heartdisease/pulmonary_hypertension.htm
3. DrugPatentWatch.com https://drugpatentwatch.com/